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Abstract  
Sepsis is a major cause for death worldwide. Numerous interventional trials with agents 
neutralizing single pro-inflammatory mediators have failed to improve survival in sepsis and 
aseptic systemic inflammatory response syndromes. This failure could well be explained by the 
widespread gene expression dysregulation known as “genomic storm” in these patients. A 
multifunctional polyspecific therapeutic agent might be needed to thwart the effects of this 
"storm". Licensed pooled intravenous immunoglobulin preparations seemed to be a promising 
candidate but they have also failed in their present form to prevent sepsis-related death. We 
report here the protective effect of a single dose of intravenous immunoglobulin preparations 
with additionally enhanced polyspecificity in three models of sepsis and aseptic systemic 
inflammation. The modification of the pooled immunoglobulin G molecules by exposure to 
ferrous ions resulted in their newly acquired ability to bind some pro-inflammatory molecules, 
complement components and endogenous “danger” signals. The improved survival in 
endotoxemia was associated with serum levels of pro-inflammatory cytokines, diminished 
complement consumption and normalization of the coagulation time. We suggest that 
intravenous immunoglobulin preparations with additionally enhanced polyspecificity have a 
clinical potential in sepsis and related systemic inflammatory syndromes.
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Introduction 
Sepsis remains a leading cause of death in intensive care units. It is the result of a severe and 
uncontrolled activation of inflammatory and coagulation pathways in response to infection, 
accompanied by a variable degree of immune paralysis (1-3). Despite adequate antibiotic therapy 
and the use of sophisticated life-supporting measures the prognosis of patients with this 
syndrome has only marginally improved in recent years. This frustrating lack of progress, 
especially when novel experimental treatments aimed to target individual mediators of 
inflammation were used, has been hard to explain so far (1, 2, 4, 5). 
A recent study has found significant changes of expression patterns of more than 80% of human 
genes (referred to as “genomic storm”) in trauma patients and bacterial LPS-injected volunteers 
with severe inflammatory response syndrome (SIRS) (6). This “genomic storm” could well 
explain the discouraging results from the efforts to treat severe generalized inflammatory 
syndromes by neutralizing a single pro-inflammatory mediator. Targeting only one or very few 
components in a system-wide network disturbance, may not be successful in exerting control. A 
multifunctional therapeutic agent may be needed instead. Passive immunotherapy with pooled 
immunoglobulin preparations (administered as intravenous immunoglobulin, IVIg) is a logical 
choice as they contain a vast array of antibody specificities, some of which could well affect key 
products of the genomic storm. In addition to antibodies that neutralize pathogens and their 
virulence factors, IVIg have diverse immunomodulatory and anti-inflammatory activities (7). 
The latter are mediated through versatile interactions with receptors on immune cells, 
components of the complement system, cytokines, etc. The outcome is down-regulation of T-, B-
lymphocyte activity and dendritic cell functions and modulation of the cytokine network (for U
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review see (7, 8)). The results from numerous clinical trials, using IVIg infusions as adjunctive 
therapy in sepsis patients have been, however, inconclusive (3, 9-11). 
All commercially available IVIg preparations are generally believed to have identical biological 
and therapeutic properties. This may not be the case as the licensed therapeutic 
immunoglobulins, produced using a fractionation step at pH 4.0 have been shown to possess an 
increased potential to bind to self-antigens (12). Importantly, this increased reactivity to antigens 
correlates with different functional activity of immunoglobulin preparation (13, 14). Thus, the 
administration of the acid pH-treated, but not of the same unmodified preparation significantly 
decreased mortality in animals with endotoxemia (12, 13). Previous studies by our and other 
groups have proven that, in addition to low pH buffers, the exposure to a number of other 
substances (e.g. ferrous ions, heme, reactive oxygen species, etc.) also increases the antigen-
binding polyspecificity of some IgG molecules (5, 15-17). IVIg modified by Fe(II) exposure 
acquired the ability to bind to the human pro-inflammatory cytokine IFN-γ and to improve 
survival in mice injected intravenously with 5.108 live E. coli or i.p with bacterial LPS (15, 18). 
Infusions of Fe-ions modified IVIg were also shown to have an anti-inflammatory activity in an 
experimental diabetes model (14). On the basis of these preliminary data we have hypothesized 
that the passive immunotherapy with pooled immunoglobulin preparations with additionally 
enhanced polyspecificity could neutralize some of the products of the genomic storm and thus 
should be beneficial in systemic inflammatory syndromes regardless of their primary insult. 
Three models of systemic inflammation in the presence or absence of infection were used to 
check this hypothesis: induced by LPS, by zymosan and by cecal ligation and puncture (CLP). 
While the infusion of native IVIg had no effect on survival, the administration of the same single 
dose of the Fe(II)-exposed IVIg improved significantly the survival of mice in all three models. 
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The studies of the mechanisms of beneficial action of the latter preparation revealed its ability to 
bind to pro-inflammatory molecules, complement components and extracellular histones. 
 
Materials and Methods 
Mice 
Outbred female ICR mice (8-12 weeks old, 18-22 g) were purchased from the Breeding Farm of 
the Bulgarian Academy of Sciences and kept in a conventional animal facility. C57Bl/6 mice (8-
12 weeks old, 18-22 g) were from Charles River Laboratories, Sulzfeld, Germany. The animals 
were housed under specific pathogen-free conditions, 6 per cage, with ad libitum access to food 
and water and maintained in a temperature-controlled environment. The animals were allowed to 
adapt to laboratory conditions for three days. The experimental protocols were approved by the 
Animal Care Commission of the Institute of Microbiology and the Thuringian State Office for 
Consumer Protection and Food Safety in accordance with National and European Regulations.  
Blood (0.05 ml / mouse) was collected from the retro-orbital sinus by a Pasteur pipette after a 
local anesthesia with 0.5% tetracaine hydrochloride and let to clot at +4 0C. Sera samples were 
aliquoted and stored at -80 °C. 
 
Experimental sepsis models 
All survival experiments were performed using ICR mice in groups of twelve animals each. 
Endotoxemia was induced by the i.p. injection of 10 mg/kg E. coli LPS (B 055:B5, #L2880, 
Sigma-Aldrich St. Luis, MO). Cecal ligation and puncture (CLP) was performed as described in 
the literature (19). Briefly, the mice were anesthetized i.p. with ketamine (80 mg/kg) and 
xylazine (10 mg/kg), a 1.5 cm long laparotomic incision was made, the cecum was ligated at 2/3 
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of its length and punctured once by a sterile 21G needle. The puncture was confirmed by a 
delicate pressing and the abdomen was closed by suture. No antibiotics or fluids were 
administered. Multiple organ dysfunction was induced by the intraperitoneal injection of 500 
mg/kg zymosan (Sigma-Aldrich) (20). The dose of the LPS or zymosan was adjusted to cause 80 
to 100% mortality in the control animals, treated with PBS only. 
 
Modified pooled therapeutic human immunoglobulins  
The intravenous immunoglobulin preparations Endobulin S/D (Baxter, Deerfield, IL) and a 
special maltose- and albumin-free batch of Immunovenin-intact (BulBio Ltd, Sofia, Bulgaria, 
kindly provided by Dr Julia Nacheva), were used in the experiments. Both preparations are 
referred to as “native”, as they are produced without using a fractionation step at acid pH (12). 
The pooled immunoglobulins were exposed to freshly prepared ferrous sulfate solution (1 mM 
final concentration) for 2 h at 4°C and then dialyzed against phosphate-buffered saline (PBS; pH 
7.4) for at least 48 h as previously described (15). In a separate experiment the ferrous ions-
modified IVIg was dialyzed against 4 mM EDTA in PBS and then against PBS. 
 
Treatment schedules 
Single dose of the native, the modified IVIg preparations or PBS alone was injected 
intravenously (i.v.) 10 min before the administration of LPS, of zymosan or at the beginning of 
CLP procedure. In all experiments survival was observed daily for seven days. 
In a separate experiment groups of animals were treated i.v. with 50 mg/kg of the native or 
Fe(II)-exposed IVIg at different time points – minutes before, one, or four hours post-LPS 
injection. 
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 Determination of serum levels of cytokines 
The levels of TNF-α, IFN-γ, IL-6, IL-10 and IL-22 in the sera obtained 4, 24 and 48 h after LPS 
injection were measured using commercial ELISA kits (PeproTech EC Ltd., London, UK). 
The Mouse inflammation antibody array kit (RayBiotech Inc., Norcross, GA). was used to 
evaluate semi-quantitatively the levels of 40-inflammation-related molecules. Briefly, 
membranes spotted with 40 capture antibodies were blocked with the manufacturer’s BSA buffer 
and incubated with the studied serum samples for 2 h at room temperature. After washing, a 
cocktail of biotinylated anti-cytokine antibodies was incubated with membranes for 2 h at room 
temperature. Membranes were then washed, incubated with HRP-conjugated streptavidin for 2 h, 
washed and exposed to the  ECL peroxidase substrate for 2 minutes. Next, the membranes were 
drained and exposed for 20 seconds to a X-ray film (Kodak X-Omat AR film). The gray color 
intensity of the spots was quantified by densitometry and analyzed using the Image-Tool v2.0 for 
Windows (UTHSCSA, San Antonio, TX, USA) software package.  
 
Measurement of plasma C3 levels 
The C3 levels in plasma were measured at 4, 24 and 48 hour after LPS administration using the 
Mouse C3 ELISA kit (GenWay Biotech Inc., San Diego, CA). 
 
Binding of modified IVIg to the C1q complement component and biological activity assays  
Increasing concentrations of native and of ferrous ions exposure-modified IVIg were added to 
the wells of a plate coated with human C1q (Calbiochem, Merck KGaA, Darmstadt, Germany). U
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Bound IgG was detected using anti-human IgG-HRP, (Fc-specific, from Southern Biotech) and 
OPD substrate. 
The ability of modified IVIg to interfere with the binding of human C1q to its ligands was 
analyzed by ELISA. C-reactive protein (from Calbiochem) or human IgG1 were coated to the 
plates at a concentration of 10 µg/ml and the wells were blocked with 2% BSA. IVIg (at 10 
mg/ml) was pre-exposed to ferrous ions (0; 0,5 and 1mM) and was mixed at 1,5 mg/ml in the 
wells of a second plate with increasing concentrations of C1q (7 serial dilutions starting from 
10µg/ml). The mixtures were transferred to the CRP- and human IgG1-coated plates. After 
incubation for 1 h at 37 oC and extensive washing, anti-C1q biotin-conjugated antibody (purified 
from goat anti-C1q antiserum from Quidel, San Diego, CA and biotinilated in house) was added 
in a 1:500 dilution. Finally streptavidin-HRP was added (from DAKO, diluted 1:1000) for 30 
minutes. After washing TMB substrate was used, the reaction was stopped with 2M sulfuric acid 
and the optical density was read at 450 nm. 
 
Coagulation and organ dysfunction tests 
Coagulation time was measured as previously described (21). Animals were bled 4 hours after 
the injection of LPS and the plasma concentrations of bilirubin and creatinine were measured by 
commercially available kits (from DIALAB GmbH, Wr. Neudorf, Austria).  
 
Detection of antibodies to cytokines and endogenous «danger» molecules in the 
immunoglobulin preparations 
The Bio-Plex Cytokine Assay (BioRad, Richmond, CA) was used to detect antibodies to human 
IL-1Ra, IL-6, IL-8, IL-10, IL-15, TNF, G-CSF, IFN-γ, IP-10, RANTES, MCP-1, MIP-1 alpha 
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and MIP-1 beta in a) the native IVIg, b) Fe(II) –exposed IVIg and c) pooled human IgM (kindly 
provided by Biotest AG, Dreieich, Germany). A human IgG1 monoclonal antibody was used as a 
control (22). The immunoglobulin preparations were added (at a concentration 200 µg/ml) to 
serial dilutions of the respective cytokines and incubated for 1 h at 37 °C following the 
manufacturer’s protocol. The presence of antibodies to mouse IFN-γ, human MIG, HMGB1 
(from HMGBiotech, Milan, Italy), recombinant human heat shock proteins (HSP 60 and HSP 70 
obtained from Enzo Life Sciences, Lausen, Switzerland) and to human histones H3 and H4 
(Roche Diagnostics, Mannheim, Germany) were tested for by ELISA. Plates (Nunc MaxiSorp) 
were coated with 2 μg/ml of the respective antigens in 0.1 M carbonate buffer and incubated 
overnight at 4 oC. After blocking and washing, the plates were incubated for 2 h at room 
temperature with increasing concentrations of the immunoglobulin preparations under study. The 
plates were then extensively washed and goat anti-human IgG antibody coupled to alkaline 
phosphatase was added and incubated for 1 h at room temperature. Immunoreactivities were 
revealed with p-nitrophenyl phosphate (Sigma-Aldrich) and the OD values were read at OD=405 
nm. 
 
Statistical analysis 
All statistical analyses were performed using the GraphPad Prism 4 software (La Jolla, CA, 
USA) and the R software (v.3.0.2). Data were expressed as mean ± SD. Differences in survival 
curves were compared using the Mantel-Haenszel test. For other data, the differences in the 
mean values between groups were analyzed with the two-tailed Student t test. Differences were 
considered significant when p < 0.05. Pearson correlation coefficient was used to compare gene 
expression profiles in different organs. 
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 Results  
Protective effect of ferrous ions-exposed IVIg improved survival in sepsis and aseptic SIRS  
The intravenous administration of a single dose of 50 mg/kg of the Fe(II)-ions-modified IVIg 
significantly decreased the mortality of animals with endotoxemia (Fig. 1A - left panel). The 
same treatment (at dose of 250 mg/kg) was protective in zymosan-induced SIRS and in 
polymicrobial CLP sepsis (Fig. 1A, middle and right panels). The survival curves of all animals 
in the experimental series are shown on Fig. S1. The native immunoglobulin preparation, 
regardless of the dose used, had no effect thus confirming results from numerous clinical trials.  
The mechanisms of protective activity of IVIg with enhanced polyspecificity in endotoxemia 
were studied in more details. The infusion of the modified IVIg one hour post-LPS injection still 
had a protective effect while the treatment delayed for 4 hours failed to improve the survival 
(Fig. 1B). The iron content of IVIg increased after the Fe(II) treatment from 0.028 mg/g IgG to 
7.2 mg/g IgG (Table S1). Nevertheless the beneficial effect of the preparation was still present 
even upon dialysis against EDTA which decreased the iron concentration (Fig. 1C). 
 
Gene expression analysis 
Microarray data of organ samples from Fe(II)-exposed IVIg treated endotoxemic mice were 
clustured by an unfiltered unsupervised approach. Unique responses to Fe(II)-exposed IVIg were 
observed in all organs, but were most pronounced in the liver, supported by a weaker correlation 
(Pearson correlation coefficient r (IVIg vs Fe(II)-exposed IVIg) = 0.83 in kidney and  r = 0.45 in 
liver). Although, several differentially expressed genes (DEG) could be identified, they did not 
constitute an easily interpretable pattern of signaling pathways (Figure S2). 
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Treatment with IVIg with enhanced polyspecificity affects plasma levels of pro- and anti-
inflammatory cytokines 
IVIg exposure to Fe(II) ions did not result in its enhanced binding to bacterial LPS (Fig. S3), 
indicating that the beneficial effect of modified IVIg was due to its interactions with host defense 
mechanisms rather than to a direct neutralization of LPS. The observed beneficial effect on 
survival suggests that the levels of pro-inflammatory molecules might be influenced by the 
treatment. Indeed, plasma levels of TNF-α, IL-6 and IFN-γ were significantly reduced in animals 
injected with modified IVIg (Fig. 2A). In contrast, the levels of IL-10 and IL-22 were 
significantly elevated. A semi-quantitative dot-blot protein array technique allowed the analysis 
of a larger panel of inflammation-related molecules. Significantly lower levels of IL-6, LIX 
(CXCL5), IL-12p70 and MIP-1gamma (CCL9) were detected after treatment with the IVIg with 
increased polyspecificity (Fig. 2B, 2C). 
 
Effect of ferrous ions-exposed IVIg on the complement system, coagulation and organ 
dysfunction of mice with LPS-induced sepsis 
Complement activation and the release of anaphylatoxins play an important role in the 
pathogenesis of sepsis (23, 24). The levels of C3 complement component in the circulation 
mirror the severity of on-going inflammation. The LPS injection resulted in a sharp and 
prolonged drop in C3 levels and the administration of the native IVIg did not significantly affect 
this level. Interestingly, the infusion of the same single dose of the IVIg with enhanced 
polyspecificity led to a significantly diminished consumption of C3 (Fig. 3A). We analyzed in 
more detail the interaction of the immunoglobulin preparations with human complement 
components. The binding of the pooled human IgG to the C1q component was enhanced after its 
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exposure to ferrous ions (Fig. 3B). While the pre-incubation of C1q with Fe(II)-exposed IVIg did 
not affect the interaction of the latter with immobilized IgG1 (not shown), it significantly 
inhibited C1q binding to CRP (Fig. 3C). Interestingly, the modified immunoglobulin preparation 
bound to C3a, but not to C5a anaphylatoxins (Fig. 3D). 
Systemic inflammation in sepsis is accompanied by an over-activation of the coagulation cascade 
and results in disseminated clots in small blood vessels, contributing to organ failure. A single 
infusion of ferrous ions-exposed IVIg to endotoxemic mice normalized the blood clotting time 
(Fig. 3E). This could well explain also the observation that liver injury was significantly 
ameliorated in the group treated with the modified IVIg as assessed by the capacity of ferrous 
ions-exposed IVIg to decrease the LPS-induced elevation of serum bilirubin levels (Fig. 3F). 
Creatinine levels at the same early time point were not affected. 
 
The Fe(II)-modified IVIg acquires additional polyspecificity that includes ability to bind 
pro-inflammatory mediators and endogenous “danger” molecules 
The exposure of therapeutic IVIg to increasing concentrations of ferrous ions results in its ability 
to bind to a broader number of antigens in a HUVEC lysate (Fig. S4). In addition, anti-human IP-
10, IFN-gamma, anti-MIG and anti-HMGBox1 reactivities were observed in Fe(II)-exposed IVIg 
using a BioPlex or ELISA assays, whereas native IVIg and pooled IgM preparations had no 
detectable antibodies to the studied cytokines. Antibodies to endogenous "danger" molecules - 
free Histone 3 and Histone 4, reported to possess a toxic effect on endothelial cells in sepsis (25), 
as well as to heat shock proteins were also present in the modified preparation (Table 1 and Fig. 
S5). 
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Discussion  
Passive immunotherapy with commercially available therapeutic IVIg exposed in vitro to a low 
concentration of pro-oxidative ferrous ions, significantly improved survival in animals with 
experimental sepsis and aseptic SIRS. The same immunoglobulin preparations were not 
protective in their native form. The improved survival was accompanied by lower serum levels 
of pro-inflammatory cytokines, normalization of the coagulation time, diminished consumption 
of C3 complement component and attenuated organ injury or dysfunction. These multimodal 
effects strongly suggest that the ferrous-exposed IVIg has acquired novel biological properties. 
Pooled IVIg are highly polyspecific therapeutic preparations. Previous studies point that their 
exposure to Fe(II)-ions or to ROS, released in inflammation sites, amplify further this 
polyspecificity (15). 
IVIg are known to suppress the harmful effects of activated complement cascade components by 
preventing their binding to the respective receptors (26). In the fluid phase the IVIg with 
enhanced polyspecificity did not perturb the capacity of C1q to recognize IgG immune 
complexes. The latter is in agreement with previous studies, showing that even at high doses 
IVIg do not alter C1q binding and complement activation on sensitized sheep erythrocytes used 
as a model of cell-bound immune complexes (27). Therefore, the administration of Fe(II) ions-
modified IVIg will not affect C1q functions during the early phase of defense against pathogens. 
Moreover, C1q binds better to the surface immobilized Fe(II) ions-modified IVIg (as a model of 
immune complex) than to the native IVIg, suggesting that the modified preparation could be 
more effective in opsonizing invading bacteria. When allowed to interact in a fluid phase with 
C1q Fe(II) ions-exposed IVIg inhibited the binding of C1q to surface-bound CRP, suggesting 
that attenuation of the complement activation on damaged host cells or on bacteria could result. 
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Since CRP levels are increased up to 50 fold in sepsis (28) the inhibition of its effector functions 
may be beneficial by reducing the ongoing inflammation. In our experiments the Fe(II) ions-
modified IVIg also showed enhanced binding to C3a anaphylatoxin expected to result in vivo in 
its rapid neutralization and elimination. 
The net beneficial effect of the blunted host response upon administration of IVIg with enhaced 
polyspecificity were reflected in less organ damage primarily in kidneys (Fig. S6). The 
transcriptome analysis showed a high variability between the individual animals suggesting that 
detection of the differential expression of particular genes might be a transitory phenomenon in a 
highly disordered (chaotic) gene network dynamics, characteristic of the septic state (29). For 
instance, some of the untreated septic animals clustered with the IVIG treated and some - with 
the modified IVIg. Nevertheless, the experiment showed detectable changes in the gene 
expression patterns, specific for the modified IVIg. A different set up with larger experimental 
groups will be necessary to trace these changes of the cascade ultimately dampening the genomic 
storm (Fig. S2). 
The idea that polyspecific natural antibodies may act as a buffering system that prevents brisk 
changes in the levels of circulating cytokines, hormones, etc., has been proposed twenty years 
ago (30). The immune-suppressive properties of plasma during sepsis have been discussed 
extensively before. Diverse factors are currently considered in this context: IL-10, extracellular 
ubiquitin, circulating CD14, epinephrine and other inducible signals (31). Such a convergence of 
different activities towards an anti-inflammatory plasma compartment indicates the importance 
of this principle. It is thus not surprising that the quasi-complete repertoire of circulating natural 
antibodies can be conditionally recruited to that function too.  U
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It is counter-intuitive that naturally polyspecific IgG antibodies should generally limit or block 
cytokine activities in the tissues. On the other hand, in vivo induced polyspecificity would be 
limited in space (to the site of inflammation) and time (IgG polyspecificity would result in a 
short half-life (32) and molecules gaining systemic access would be quickly diluted). Thus, its 
effect would be tightly controlled. It is possible that the in vitro treatment of IVIg with protein-
destabilizing agents serendipitously activated this function on a large scale. Intravenous infusion 
of immunoglobulin preparation with additionally enhanced polyspecificity would apply 
systemically a “buffer” system that evolution have meant to have a local effect. During the event 
of uncontrolled systemic inflammation (sepsis) this may be helpful as it would enhance the 
inherent anti-inflammatory activity of plasma. Our data provide evidence to support this 
hypothesis as only the modified, but not the native IVIg preparation binds to a) a panel of 
antigens in a HUVEC lysate, b) mediators of inflammation – IFNγ, IP-10/CXCL10, 
MIG/CXCL9 and HGMB1, c) the complement components C1q and C3a, and d) the 
hydrophobic "danger signals" heat shock proteins and the free extracellular histones H3 and H4 
(see Refs. (15, 25) and Figs. 3, S4 and S5). Importantly, our studies revealed that Fe(II) ions 
exposure is associated with considerable increase in the hydrophobicity of antigen binding sites 
of IgG (15). As endogenous danger signals have frequently hydrophobic nature, antibody-
mediated non-specific quenching of hydrophobicity may also well explain the systemic anti-
inflammatory effect of modified IVIg (33, 34). 
Furthermore, the elimination of the formed immune complexes by Fc receptor-expressing 
phagocytes may contribute to the down-regulation of the ongoing severe generalized 
inflammatory reaction. U
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Although the dependence of the observed therapeutic effect of modified IVIg on lymphocytes 
and macrophages is compatible with the “immunosomatics” mechanism (30), an effect, mediated 
by a particular mononuclear cell population, cannot be ruled out. Innate response activator (IRA) 
CD19lowCD5lowCD93+ B cells have been implicated recently in the control of experimental 
sepsis in mice (35). Indeed, our recent studies show that, unlike native IVIg, ferrous ions 
exposure-modified IVIg induced in the LPS-injected mice higher levels of IRA B cells and the 
beneficial effect of the treatment on survival correlated with this increase (36). 
 
Conclusion 
This work contains evidence that pleiotropic therapeutic approaches offer a viable strategy for 
treatment of sepsis and aseptic SIRS. Apart from the mechanistic explanation, the pleiotropy 
principle also justifies the use of mouse models despite the controversy on differences in 
transcriptome profiles in humans and mice with severe inflammatory syndromes (37, 38).  
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Table 1. Exposure of IVIg to ferrous ions results in the appearance of reactivity to some of the 
tested human cytokines, complement components and “danger” molecules. Antibody reactivity 
to mouse IFN-γ were measured in a control ELISA experiment. NS* - not shown. 
 Inflammation-related 
and "danger" molecules 
Binding appears 
after IVIg 
exposure to 
ferrous ions  
Method used Reference 
 Cytokines 
1 MIG Yes ELISA Fig. S5 
2 IP-10 Yes BioPlex Array Fig. S5 
3 HMGB1 Yes ELISA Fig. S5 
4 IFN-γ Yes BioPlex Array Fig. S5 and 
Ref.15 
5 Mouse IFN-γ No ELISA Fig. S5 
6 IL-8 No BioPlex Array NS 
7 IL-10 No BioPlex Array NS 
8 IL-15 No BioPlex Array NS 
9 G-CSF No BioPlex Array NS 
10 MCP-1 No BioPlex Array NS 
11 MIP-α No BioPlex Array NS 
12 MIP-β No BioPlex Array NS 
13 TNF-α No BioPlex Array Fig. S5 
14 IL-6 No ELISA NS 
15 IL1-RA No ELISA NS 
16 RANTES No BioPlex Array NS 
 Complement components 
17 C1q Yes ELISA Fig. 3B 
18 C3a Yes ELISA Fig. 3D 
19 C5a No ELISA Fig. 3D 
 “Danger” molecules 
20 Histone 3 Yes ELISA Fig. S5 
21 Histone 4 Yes ELISA NS 
22 HSP 60 Yes ELISA Fig. S5 
23 HSP 70 Yes ELISA Fig. S5 
24 HSP 90 Yes ELISA NS 
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 Figure legends: 
Figure 1. Passive immunotherapy with IVIg modified by Fe(II) exposure improves animal 
survival in two aseptic SIRS and one polymicrobial sepsis models. Outbred female ICR mice 
were used in the experiments. (A) Endotoxemia was induced by the i.p. injection of 10 mg/kg E. 
coli LPS (left panel). Zymosan-induced systemic inflammation (middle panel) was caused by i.p. 
injection of 500 mg/kg zymosan. Polymicrobial CLP-induced sepsis (right panel) was performed 
as described in the Materials and methods section. The survival was compared between the 
control group, injected i.v. with PBS (open squares, n = 12), the group with endotoxemia treated 
with 50 mg/kg or of 250 mg/kg (in zymosan-induced inflammation and CLP sepsis) native IVIg  
(triangles, n = 12), and a group treated with 50 mg/kg (endotoxemia) or 250 mg/kg (zymosan-
induced inflammation and CLP sepsis) Fe(II)-exposed IVIg  (circles, n = 12); *p<0.05, Mantel-
Haenszel logrank test). (B) The beneficial effect of the Fe(II)-exposed preparation on survival 
was still observed if its administration was delayed. Endotoxemia was induced as described 
above and the mice were treated i.v. with 50 mg/kg of the native (open bars) or Fe(II)-exposed 
IVIg (black bars) at different time points – minutes before, one, or four hours after the i.p. 
injection of LPS. (C) Residual iron ions in Fe(II)-exposed IVIg did not contribute to its 
protective effect in LPS sepsis. ICR mice (n=12) were injected i.p with 10 mg/kg E. coli LPS 
and treated i.v. with 50 mg/kg Fe(II)-exposed IVIg with high (7.2 mg/g IgG, black circles) or 
low (0.66 mg/g IgG, white circles) iron concentration or with PBS only (open squares). 
 
Figure 2. Serum levels of inflammation-related molecules in treated endotoxemic mice. (A) 
Endotoxemia was induced by the i.p. injection of 10 mg/kg E. coli LPS. A control group was 
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injected i.v. with PBS (n = 10, light grey bars), a second group was injected i.v. with 50 mg/kg of 
native IVIg  (n = 10, dark grey bars), and a third group - with 50 mg/kg of Fe(II)-exposed IVIg  
(n=10, black bars). Cytokine levels in untreated mice are represented with white bars. Sera were 
obtained 4, 24 and 48 h after LPS injection and cytokine levels were measured by ELISA. Data 
represent mean pg/ml values±SD of quadruplicate wells, *p<0.05 (paired Student t-test). (B) 
Scan of dot blots evaluating semi-quantitatively of serum levels of a larger panel of 
inflammatory molecules two hours after LPS injection. Each blot is representative of three 
individual experiments. (C) The individual dots (see panel B) were subjected to densitometry and 
the data were analyzed using the Image-Tool v2.0 for Windows (UTHSCSA, San Antonio, TX, 
USA) software package and were represented in relative units of grey intensity (n=3, mean±SD, 
*p<0.05, paired Student t-test).  
 
Figure 3. A single administration of Fe(II) exposure-modified IVIg overcomes the 
coagulation and complement abnormalities in LPS-induced sepsis. (A) Endotoxemia was 
induced to ICR mice by the i.p. injection of 10 mg/kg E. coli LPS. A control group (n=10, open 
squares) was injected i.v. with PBS, a second group was treated with 50 mg/kg native IVIg  (n = 
10, black triangles), and a third was treated with 50 mg/kg Fe(II)-exposed IVIg  (n=10, black 
circles). Serum samples were collected at 4, 24 and 48 hour after LPS administration and the C3 
levels in plasma were measured using a commercial Mouse C3 ELISA kit, *p<0.05, paired t-test. 
(B) The exposure of IVIg to Fe(II)-ions results in its increased binding to C1q molecules (black 
circles) compared to that of native IVIg (black triangles), mean±SD. (C) C1q pretreatment with 
Fe(II)-exposure modified IVIg inhibits the binding of the former to CRP (black circles); in 
comparison to C1q pretreated with native IVIg (black triangles). The binding of untreated C1q is 
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presented with open squares. (D) The exposure of IVIg to increasing concentrations of ferrous 
ions results in an enhanced binding to the C3a, but not the C5a component Anti-C3a and anti-
C5a reactivity was compared by ELISA in IVIg, exposed to increasing concentrations of ferrous 
ions. (E) Endotoxemia was induced to ICR mice by the i.p. injection of 10 mg/kg E. coli LPS. A 
control group was treated i.v. with PBS (n=10, light grey bars), a group was treated with 50 
mg/kg native IVIg (n = 10, dark grey bars), and another was treated with 50 mg/kg Fe(II)-
exposed IVIg  (n=10, black bars). Animals were bled 4 hours after the injection of LPS and 
coagulation time was measured as previously described (21), *p<0.05; ***p<0.001, t-test. (F) 
Bilirubin serum levels measured four hours after LPS administration in groups of mice treated 
with native (n=10, dark grey bars), Fe(II) -exposed IVIg (n=10, black bars) or PBS alone (n=10, 
light grey bars). *p<0.05, t-test. 
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Supporting information: 
 
 
Materials and Methods  
 
Flame atomic absorption spectroscopy 
 
The concentration of iron ions in the IVIg preparations under study was measured by flame 
atomic absorption spectrometry. The samples were diluted 1:2 with a 20% (W/V) trichloro 
acetic acid solution, and heated in a heating block for 15 minutes at 90°C. They were next 
cooled, centrifugated and the iron concentration was determined using a Perkin Elmer M 5000 
atomic absorption spectrometer. 
 
Gene expression analysis 
C57Bl/6 mice were used in this analysis. Blood samples, liver and kidney homogenates were 
obtained and processed by standard protocols. RNA was extracted using the RNeasy minikit 
(Qiagen, Hilden, Germany) in a balanced design comprising three biological replicates from 
blood and four from liver and kidney of each treatment group (vehicle, native IVIg, Fe(II)-
exposed IVIg) respectively. Biotinylated probes were prepared using the TargetAmp™-Nano 
Labeling Kit for Illumina® Expression BeadChip® (Illumina, San Diego, CA). The arrays 
were scanned using the Illumina BeadArray Reader 500 X. 
Illumina mouseRef8 V2 chips were read by Genome Studio (v.1.9, and annotation MouseRef-
8_V2_0_R3_11278551_A) yielding 25,697 bead probes for each sample. Analysis was 
performed consistently using R software version 3.02 (http://www.r-project.org/) and 
Bioconductor (1) packages. Raw data from each organ was separately subjected to robust 
spline normalization, quality control and background correction with the R package Lumi (2). 
Two samples (one from blood cells, one from kidney) did not pass quality control and were 
discarded from analysis. Bead types having detection values p < 0.05 of the RNA samples 
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were called "present" and taken for further analysis. Differentially expressed genes (DEG) 
were filtered according to microarray quality control criteria (MAQC, (3)) by: 1) at least two-
fold changes and 2) p-values from moderated t-statistics <0.05 using ”Limma” (24). Further, 
these statistics were computed for all the contrasts (IVIg, Fe(II) exposure-modified IVIg 
(modIVIg), vehicle) using linear model fits, moderated t-and F-statistics, and log-odds of 
differential expression by empirical Bayes moderation. Gene set enrichment analysis was 
performed by hypergeometric tests with the WebGestalt tool (4). Annotation, log2 fold 
changes, top enriched categories and p-values are provided as Supplemental gene expression 
data. 
 
Binding of and modified IVIg to bacterial lipopolysaccharide 
 
ELISA plates were coated with E. coli LPS (B 055:B5, Sigma #L2880, at 5 ug/ml in PBS) 
and blocked. Serial dilutions of the IVIg preparations were added in triplicate wells and the 
binding  of the pooled human IgG was measured by ELISA. 
In a separate experiment the native- and the Fe(II)-exposed IVIg were mixed in the wells of 
a blocked ELISA plate with increasing concentrations of E.coli LPS and incubated for two 
hours at room temperature. These mixtures were transferred to a second LPS-coated plate 
and the binding of human IgG was measured by ELISA as described in the Methods section. 
Its inhibition in the presence of free LPS was determined and presented in arbitrary units. 
 
Immunoblot analysis of binding to HUVEC antigens 
 
HUVEC cells lysates were subjected to 10% gel SDS-PAGE and transferred to nitrocellulose 
membranes (Scheicher & Schuell, Dassel, Germany) by a Mini Transfer Blot system 
(BioRad, Richmond, CA). Next, the membranes were incubated for 1 hour at room 
temperature in TBS containing 0,4% Tween 20, cut into strips and incubated for 1 h at room 
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temperature with native or Fe(II)-exposed IVIg preparations at concentrations of 0,2 mg/ml. 
After extensive washing the strips were incubated with an anti-human IgG antibody (Fc-
specific), conjugated to alkaline phosphatase (Sigma Chemical Co, St. Louis, MO) and 
revealed using the nitro blue tetrazolium/bromo-chloro-indolyl-phosphate substrates (Sigma). 
 
Antibodies to pro-inflammatory and “danger” molecules in the modified IVIg 
The presence of antibodies to cytokines, complement components and “danger” molecules 
was studied using ELISA and BioPlex Array (see the Materials and Methods section of the 
main text). 
 
Histology 
 
ICR mice (8-12 weeks old, 18-22 g) were used in this experiment. Endotoxemia was induced 
by the i.p. injection of 10 mg/kg E. coli LPS (B 055:B5, #L2880, Sigma-Aldrich St. Luis, 
MO). Single dose of native, modified IVIg preparations or PBS alone was injected 
intravenously (i.v.) 10 min before the administration of LPS. Kidneys and livers from each 
experimental group were collected 24 h after the injection of LPS. The organs were fixed in 
4% buffered formalin, embedded in paraffin, sectioned into 3.5 µm thick slices and stained 
with Hematoxylin and Eosin (H&E). Pathologists blinded for the treatments estimated kidney 
damage in mice challenged with LPS + vehicle (n=8), LPS + native IVIg (n=10), LPS + 
Fe(II)-exposed IVIg (n=10) using the following criteria: the presence of brush-border defects, 
flattening of epithelia, loss of nuclei and presence of debris all indicative of an acute tubular 
injury (ATI) (5). Presence of liver damage was graded based on sinusoidal congestion, 
nuclear and cytoplasmic irregularities, signs of cellular ischemia, sinusoidal infiltration and 
single cell necrosis (6). 
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Table S1. The concentration of iron in the studied immunoglobulin preparations was 
measured by atomic absorption spectrometric analysis. 
Preparation Iron concentration 
Native (untreated) IVIg 0.028 mg/g IgG 
Fe(II)-exposed IVIg 7.2 mg/g IgG 
Fe(II)-exposed IVIg dialyzed additionally 
against 4mM EDTA 
0.66 mg/g IgG 
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Figure legends: 
 
Figure S1. Reduced mortality in three different experimental models of sepsis after 
passive immunotherapy with an IVIg preparation, modified by Fe(II) exposure. (A) 
Survival curves of ICR mice with bacterial LPS-induced endotoxemia. Animals were injected  
i.p.  with  10 mg/kg E. coli LPS. A survival study was performed comparing a control group, 
treated i.v. with PBS (open squares, n = 12), a group treated with 2 mg/kg (left panel), 10 
mg/kg (middle panel) or 50 mg/kg (right panel) native IVIg (triangles, n = 12), and a group 
treated with 2 mg/kg (left panel), 10 mg/kg (middle panel) or 50 mg/kg (right panel)  Fe(II)-
exposed IVIg  (circles, n = 12); *p<0.05, Mantel-Haenszel logrank test). (B) Survival curves 
of ICR mice with  zymosan-induced systemic inflammation. Animals were injected i.p. with 
500 mg/kg zymosan. A survival study was performed comparing a control group, treated i.v. 
with PBS (open squares, n = 12), a group treated with 10 mg/kg (left panel), 50 mg/kg 
(middle panel) or 250 mg/kg (right panel) native IVIg (triangles, n = 12), and a group treated 
with 10 mg/kg (left panel), 50 mg/kg (middle panel) or 250 mg/kg (right panel) Fe(II)-
exposed IVIg (circles, n = 12); *p<0.05, Mantel- Haenszel logrank test). (C) Survival curves 
of ICR mice with polymicrobial CLP-induced sepsis. Survival was compared between a 
control group, injected i.v. with PBS (open squares, n = 12), a group treated with 10 mg/kg 
(left panel), 50 mg/kg (middle panel) or 250 mg/kg (right panel) of native IVIg (triangles, n = 
12), and a group treated with 10 mg/kg (left panel), 50 mg/kg (middle panel) or 250 mg/kg 
(right panel) of Fe(II)-exposed IVIg (circles, n = 12). *p<0.05, Mantel- Haenszel logrank 
test). 
 
Figure S2. Blood cell, liver and kidney gene expression in LPS-injected mice treated 
with native- or Fe(II)-exposed IVIg (modIVIg). Heatmaps depicting the differentially 
expressed genes (DEG, average two-fold change and p<0.05) for Fe(II)-exposed IVIg versus 
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native IVIg in blood (A), liver (B) and kidney (C), respectively. Resolved log2 signals of 
biological replicates were row-wise scaled (z-score) accompanied by vertical and horizontal 
hierarchical correlation clustering (technical probe replicates are indicated by ".1". Definition 
of gene symbols is provided in the supplement files. The Venn diagrams depict the number of 
DEG for all contrasts (D).  
 
Figure S3. The exposure of IVIg to ferrous ions does not affect its binding to LPS. (A) 
Increasing concentrations of native- and Fe(II)-exposed IVIg preparations (marked with 
squares and circles respectively) were left to interact with immobilized LPS and human IgG 
binding was evaluated by ELISA. (B) Both preparations were pre-incubated with increasing 
concentrations of LPS and the mixtures were transferred to the LPS-coated wells. Next, the 
binding of human IgG was measured by ELISA and its inhibition (presented in arbitrary units 
- AU) was plotted against the concentration of free LPS used. 
 
Figure S4. Exposure of IVIg to increasing concentrations of Fe(II) ions results in its 
enhanced binding to antigens in a HUVEC lysate. The membranes were incubated with 
200 µg/ml of the native IVIg or of the same preparation exposed to ferrous ions. 
 
Figure S5. Ferrous ions-exposed IVIg acquires the ability to bind to various human 
pro-inflammatory molecules. The figure presents several examples whereas all results are 
showed in Table 1 of the main text. Reactivity to IFN-γ , ΙP−10 and ΤΝFα were  measured 
using BioPlex Array and in all other cases ELISA was used (see the Materials and Methods 
section of the main text). In a control experiment the reactivities of both studied preparations 
to mouse IFN-γ (mIFN-γ ) were compared. The pie-chart summarizes all data and points out 
that modified IVIg acquires the ability bind to almost half of the unselected tested 
inflammation-related molecules. 
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Figure S6. Tissue damage score from histological specimen (kidney - A and B, liver - C 
and D) from mice with endotoxemia treated with native or Fe(II)-exposed IVIg. Kidney 
injury was evaluated by the presence of brush-border defects, flattening of epithelia, loss of 
nuclei and presence of debris, summarized in the acute tubular injury (ATI) score (1). Liver 
damage scoring was based on sinusoidal congestion, nuclear and cytoplasmic irregularities, 
signs of cellular ischemia, sinusoidal infiltration and single cell necrosis. Summaries are 
provided in A and C for kidney and liver, respectively. *p<0.05, t-test (Welch-modified, 
accounting for differences in variances) Fe(II)-exposed IVIg vs the other groups given in 
parametric plots. 
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ILMN_Gene average log2FC IVIg-Vehicle modIVIg-Vehicle modIVIg-IVIg P (moderated t-statistics) IVIg-Vehicle modIVIg-Vehicle modIVIg-IVIg Probe_Id Probe_Sequence Definition
2900062L11RIK -1.416697695 -0.173654787 1.243042908 0.037431 0.775410146 0.0463929 ILMN_2609182 CCTTGTAGGTCCACATTGAATGCCGTTTTCTTATATCTTCTAGGGTGTGT Mus musculus RIKEN cDNA 2900062L11 gene (2900062L11Rik), non-coding RNA.
ADFP -0.594814157 0.717284553 1.31209871 0.0968802 0.051508139 0.00135786 ILMN_1222246 AGAAAATTCAGGGTGCTCAGGATAAGCTCTATGTCTCGTGGGTGGAGTG Mus musculus adipose differentiation related protein (Adfp), mRNA.
ADIPOQ -2.400097295 0.232938434 2.633035729 0.011571 0.771813749 0.00439888 ILMN_2738082 GACTGCAACTACCCATAGCCCATACACCAGGAGAATCATGGAACAGTCG Mus musculus adiponectin, C1Q and collagen domain containing (Adipoq), mRNA.
AOC3 -1.531980725 -0.312202827 1.219777897 0.0366476 0.63477318 0.06509666 ILMN_2625920 GAGAGGGAATCAGGTTCTGCCTGCCCTTCTGAACATCATGGATTGGAAC Mus musculus amine oxidase, copper containing 3 (Aoc3), mRNA.
APOC1 -1.299479683 -0.347932302 0.951547381 0.0479402 0.560706361 0.10537082 ILMN_2599794 AAAGTGAAGGAGAAGTTGAAGACCACGTTCTCCTGAGCACCTGGCGGGCMus musculus apolipoprotein C-I (Apoc1), mRNA.
AQP4 -1.01024592 -1.330365875 -0.320119956 0.0777703 0.026900839 0.51716872 ILMN_2757232 GTGCAGAGCATATGGACACCTCTGTGAGGAAGCTGGCATTGTCCATCGT Mus musculus aquaporin 4 (Aqp4), mRNA.
CAR3 -1.362158574 -0.203605447 1.158553127 0.0381835 0.729427688 0.05319186 ILMN_2630047 CCCTGGCTCTGCTAAGACCATCCTGAACAATGGGAAGACCTGCAGAGTT Mus musculus carbonic anhydrase 3 (Car3), mRNA.
CCND1 0.381308916 -0.86206292 -1.243371836 0.3771588 0.062804125 0.00844535 ILMN_2601471 GCCATAGACTGGTGGTGGGTCCACGGAATCTGCCCTGTGACATGAAAGGC
CCND1 0.398618927 -0.770912202 -1.169531129 0.3564935 0.090707034 0.01173754 ILMN_1221503 GGCCATAGACTGGTGGTGGGTCCACGGAATCTGCCCTGTGACATGAAAGG
CD1D1 -1.46195839 -0.084498452 1.377459938 0.028787 0.886047215 0.02663035 ILMN_2734212 GAACTAGAAAGCATACTTCCTGCCCAAACAGACGCTCTGAGGTTAGTTG Mus musculus CD1d1 antigen (Cd1d1), mRNA.
CDKN1A -0.598236148 0.649996258 1.248232406 0.2810181 0.243870608 0.02766547 ILMN_2634083 CATCCTGGTCTGGACTGTCTACCCTTAGCCCGCACCCCAAGAACATGTA Mus musculus cyclin-dependent kinase inhibitor 1A (P21) (Cdkn1a), mRNA.
CFD -2.965653662 0.530765528 3.496419189 0.0049065 0.536798053 0.0010017 ILMN_2835423 CAGTCGAAGGTGTGGTTACGTGGGGCTCTCGCGTCTGTGGCAATGGCAAMus musculus complement factor D (adipsin) (Cfd), mRNA.
CIDEA -1.801244902 -0.559559857 1.241685045 0.0150816 0.385987296 0.05452063 ILMN_1215446 GACGGGACAGTTCCTGGTCTATGCGGGCACATACATGCTCCGAGTACTGMus musculus cell death-inducing DNA fragmentation factor, alpha subunit-like effector A (Cidea), mRNA.
CIDEC -1.456853318 -0.138919218 1.317934099 0.0081337 0.761195691 0.00924771 ILMN_1222679 GAGGTGTGCGAGAGAGTGTTAGAGGTGGAGATTAACTAAAGCCGGCATGMus musculus cell death-inducing DFFA-like effector c (Cidec), mRNA.
CLDN11 -1.645730543 -1.42116018 0.224570363 0.0191203 0.036851878 0.69063747 ILMN_1246139 GTGTCTAAGACTCTGGATACTGCAAGCTCCGTCCGGTGCATTTGTTCAG Mus musculus claudin 11 (Cldn11), mRNA.
COX8B -2.449745171 -0.250312233 2.199432937 0.0265011 0.796554407 0.03034856 ILMN_2727520 CGTTGGCTTCATGGTTCCAGCAGGATGGGTCTTAGCCCACTTGGAGAGC Mus musculus cytochrome c oxidase, subunit VIIIb (Cox8b), mRNA.
GNA14 0.487424158 -0.52936533 -1.016789488 0.3000355 0.262600443 0.03319393 ILMN_2597778 GCGCTGTGCCTTTCTGGATACTAAGAATACACTGTTCTACCCTGAACACCMus musculus guanine nucleotide binding protein, alpha 14 (Gna14), mRNA.
HAVCR1 -0.172270347 1.403494432 1.575764778 0.7857277 0.045698769 0.01981639 ILMN_2604307 AAGCTTTGCAGAACGCAGCGGTTGTGCATTCCCGAGCTGAAGACAACAT Mus musculus hepatitis A virus cellular receptor 1 (Havcr1), mRNA.
HP -2.096151341 0.392517347 2.488668689 0.0132898 0.587818322 0.00317183 ILMN_2668509 CTGTTGTCACTCTCCTGCTCTGGGGTCAGCTTTTTGCTGTGGAGTTGGG Mus musculus haptoglobin (Hp), mRNA.
HP -2.204083306 0.44858963 2.652672936 0.0217303 0.593855579 0.00538841 ILMN_2668510 CTCTCCTGCTCTGGGGTCAGCTTTTTGCTGTGGAGTTGGGCAATGATGC Mus musculus haptoglobin (Hp), mRNA.
HP -2.332394507 0.611622015 2.944016523 0.0117124 0.44034818 0.00181362 ILMN_2944824 ACGAGTCCCGTTGGGGTCCAGCCTATCTTGAACGAGCACACCTTCTGTG Mus musculus haptoglobin (Hp), mRNA.
IGFBP5 -0.499217044 -1.072298018 -0.573080974 0.272493 0.031436343 0.18029713 ILMN_2964324 GGATAGTACAGTTCAGACAAGACTCCTTCAGATTCCGAGACGCCTACCG Mus musculus insulin-like growth factor binding protein 5 (Igfbp5), mRNA.
IL4I1 -0.391947595 -1.081478706 -0.689531111 0.3802022 0.029367298 0.11131137 ILMN_2733778 CCCAGCTCCTAAGCCAGCCCTCTTCAGGGCAGACAGACCACCTACACTA Mus musculus interleukin 4 induced 1 (Il4i1), mRNA.
ITIH4 -0.746467905 0.417565978 1.164033883 0.1420903 0.394031883 0.02270197 ILMN_2718431 CACCTTATGCCAACAGGGACGCCTGTGAGGCCGAGACCTTGATGGGAAGMus musculus inter alpha-trypsin inhibitor, heavy chain 4 (Itih4), mRNA.
KRT20 0.083357367 1.757084824 1.673727457 0.8930599 0.015346426 0.01327319 ILMN_2907285 GTGAACGGGTTCTCCAGGGAGGCAACTTCCCAGTTAATCTCATTGTCTCCMus musculus keratin 20 (Krt20), mRNA.
LOC100043671 -1.456136503 -0.593052178 0.863084325 0.0369099 0.351242413 0.15502824 ILMN_1258600 TCTGTCCACTTGTTCACAAAGCAGCCTTCACACGTGTCAGTGAGAGTTCGPREDICTED: Mus musculus hypothetical protein LOC100043671 (LOC100043671), mRNA.
MFSD2 -1.051508402 0.381609069 1.433117471 0.097658 0.522914016 0.02253908 ILMN_1225764 AGGGCTGCTACTGTGAATATGCCAAGGACTGACTGGGCCTAGCTCGGAAMus musculus major facilitator superfamily domain containing 2 (Mfsd2), mRNA.
MYCL1 -0.022587085 1.064445119 1.087032205 0.9557901 0.022773331 0.01412011 ILMN_1221750 GGGACTCCTGGAACTATCTTGGGAGGACAAGTGGTGAACAGGCTAAAGTMus musculus v-myc myelocytomatosis viral oncogene homolog 1, lung carcinoma derived (avian) (Mycl1), mRNA.
MYL1 -1.077625097 -0.343423488 0.734201609 0.0333534 0.451390027 0.10004509 ILMN_2878542 GATAATCTCAAGTCCACACACCACCGTTATCATCTACTTGGGTCCACAAC Mus musculus myosin, light polypeptide 1 (Myl1), mRNA.
NNMT -1.199571192 0.25428225 1.453853442 0.0678093 0.674137856 0.0229501 ILMN_2885277 CTCCCTAGTGGGGCGAAAGCCAGGCAGATCTGAATGACATCCTGTGATC Mus musculus nicotinamide N-methyltransferase (Nnmt), mRNA.
ORM1 -2.030115548 -0.101961618 1.92815393 0.0352627 0.905436355 0.03164228 ILMN_1226935 CCTTTGCCCACCTTATAGTGCTGAGGAAACATGGGGCCTTCATGCTTGC Mus musculus orosomucoid 1 (Orm1), mRNA.
S3-12 -1.472158014 0.190004481 1.662162495 0.0228048 0.736759772 0.00826673 ILMN_2588249 CCTTAGTGTCTGCTTCACTCAAGCTGGTAGAACAGGCTACTCGCTGCAC Mus musculus plasma membrane associated protein, S3-12 (S3-12), mRNA.
SAA3 -0.78514295 0.678302447 1.463445398 0.1322338 0.187289026 0.00786362 ILMN_2772632 GAGGACTCAAGAGCTGACCAGTTTGCCAATGAGTGGGGCCGGAGTGGC Mus musculus serum amyloid A 3 (Saa3), mRNA.
SCD1 -1.647443514 -0.537645069 1.109798445 0.0044752 0.263470449 0.02437171 ILMN_1237375 CCAGTCAAAGTGCAAGACTACCTACCCACTGCCATGAAAACCATTGCAG Mus musculus stearoyl-Coenzyme A desaturase 1 (Scd1), mRNA.
SCIN -0.002361753 -1.293221152 -1.290859399 0.9945273 0.003086022 0.00188657 ILMN_1259174 GCTTCTAAGCATTTCCCCGTCTGCTACTCTGTTTGCAGTGAGCTTTACTT Mus musculus scinderin (Scin), mRNA.
SERPINA3C -1.001675207 0.217593835 1.219269043 0.0171768 0.550762992 0.00373395 ILMN_2730054 CAAGGGACTCATCTCAGACCTGGATACGGATACACTGATGGTGCTGGTG Mus musculus serine (or cysteine) peptidase inhibitor, clade A, member 3C (Serpina3c), mRNA.
SERPINA3M -0.885792445 0.417494031 1.303286476 0.03249 0.270410176 0.00270448 ILMN_2728473 CCTCTTTATGGCCAAAGTCACTAACCCCAAGTGAACCTAAAGCTCCCCAAMus musculus serine (or cysteine) peptidase inhibitor, clade A, member 3M (Serpina3m), mRNA.
SERPINA3N -1.378347276 0.440050877 1.818398152 0.0343426 0.453636705 0.00575328 ILMN_1246800 CCCCTGGCACTCCTACTTAGAACAAAGTAGCCTTTCTTTTAGTTCCCAGC Mus musculus serine (or cysteine) peptidase inhibitor, clade A, member 3N (Serpina3n), mRNA.
SGK2 0.533528881 1.0746424 0.541113519 0.1507394 0.010434508 0.11899333 ILMN_2827080 GGCTGCCCAGAAACCGTCTGGTGGCTTCCTTTAGTGTGTCGTAAATCTC Mus musculus serum/glucocorticoid regulated kinase 2 (Sgk2), mRNA.
SGK2 0.639027332 1.000316869 0.361289537 0.0772857 0.011458472 0.25746565 ILMN_2827081 GAGAGAAAGGGGAGGATGTAGGTGACCAGCACTCTGGGAGAGAGCCTC Mus musculus serum/glucocorticoid regulated kinase 2 (Sgk2), mRNA.
SLC1A3 -1.259241472 0.321836021 1.581077493 0.040451 0.562001189 0.00954689 ILMN_2634317 CCCGGGCTCTGCCTATGTGTGTACCCACTGTGGACTGGGAAACTTCACT Mus musculus solute carrier family 1 (glial high affinity glutamate transporter), member 3 (Slc1a3), mRNA.
SLC4A1 0.52824231 -0.744134243 -1.272376553 0.0751733 0.018739204 0.00039945 ILMN_1227675 CGCTCTTCCCCCACCGCCGTGCTTGGGAATAGGTTTTGCCAATAAACGT Mus musculus solute carrier family 4 (anion exchanger), member 1 (Slc4a1), mRNA.
SLC5A3 0.750679233 1.037239005 0.286559772 0.0513856 0.012004863 0.38412317 ILMN_1233078 CCCAGTGGCTTCCATGGGTCATTCAGAGGCAGAAACACCAGTAGATGCT Mus musculus solute carrier family 5 (inositol transporters), member 3 (Slc5a3), mRNA.
TMEM174 0.249557844 -0.848911432 -1.098469276 0.414559 0.015675558 0.00224195 ILMN_1216425 GGCTGCCCCCAAGAGAGATACAGGAATTGTCAGGTCTTGAAGGTTTTGG Mus musculus transmembrane protein 174 (Tmem174), mRNA.
TRF -1.477109112 0.245021332 1.722130444 0.0175221 0.648774584 0.00498246 ILMN_2485323 CTGGGGTAGACAGAACCGCTGGTTGGAACATCCCTATGGGCATGCTGTAMus musculus transferrin (Trf), mRNA.
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Index UserID Value Gene Symbol Gene Name EntrezGene Ensembl
1 
ILMN_288
3392 NA S100a11
S100 calcium binding 
protein A11 
(calgizzarin) 20195
ENSMUS
G0000002
7907
2 
ILMN_280
3674 NA S100a9
S100 calcium binding 
protein A9 
(calgranulin B) 20202
ENSMUS
G0000005
6071
3 
ILMN_271
2120 NA S100a6
S100 calcium binding 
protein A6 (calcyclin) 20200
ENSMUS
G0000000
1025
4 
ILMN_269
1780 NA Myl3
myosin, light 
polypeptide 3 17897
ENSMUS
G0000005
9741
5 
ILMN_271
0905 NA S100a8
S100 calcium binding 
protein A8 
(calgranulin A) 20201
ENSMUS
G0000005
6054
Index UserID Value Gene Symbol Gene Name EntrezGene Ensembl
1 
ILMN_271
2986 NA Chi3l3 chitinase 3-like 3 12655
ENSMUS
G0000004
0809
2 
ILMN_123
6889 NA Selp selectin, platelet 20344
ENSMUS
G0000002
6580
3 
ILMN_266
9486 NA Oxt oxytocin 18429
ENSMUS
G0000002
7301
4 
ILMN_271
4796 NA Coro1a
coronin, actin binding 
protein 1A 12721
ENSMUS
G0000003
0707
5 
ILMN_122
8475 NA Ulk1 unc-51 like kinase 1 22241
ENSMUS
G0000002
9512
6 
ILMN_276
6604 NA Camp
cathelicidin 
antimicrobial peptide 12796
ENSMUS
G0000003
8357
Database:molecular function       Name:calcium ion binding       ID:GO:0005509
C=479; O=5; E=0.94; R=5.32; rawP=0.0022; adjP=0.0336
Database:cellular component       Name:cytoplasmic membrane-bounded vesicle       ID:GO:0016023
C=506; O=6; E=1.00; R=6.01; rawP=0.0004; adjP=0.0088
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Liver
Index UserID Value Gene Symbol Gene Name EntrezGene Ensembl
1 230073 NA Ddx58
DEAD (Asp-Glu-Ala-Asp) 
box polypeptide 58 230073
ENSMUSG000000402
96
2 107569 NA Nt5c3
5'-nucleotidase, cytosolic 
III 107569
ENSMUSG000000297
80
3 76654 NA Upp2 uridine phosphorylase 2 76654
ENSMUSG000000268
39
4 240549 NA Gm4952 predicted gene 4952 240549
ENSMUSG000000716
33
5 225913 NA Dak
dihydroxyacetone kinase 2 
homolog (yeast) 225913
ENSMUSG000000343
71
6 58185 NA Rsad2
radical S-adenosyl 
methionine domain 
containing 2 58185
ENSMUSG000000206
41
7 13119 NA Cyp4a14
cytochrome P450, family 
4, subfamily a, polypeptide 
14 13119
ENSMUSG000000287
15
8 21743 NA Inmt
indolethylamine N-
methyltransferase 21743
ENSMUSG000000034
77
9 17857 NA Mx1
myxovirus (influenza virus) 
resistance 1 17857 NULL
10 17246 NA Mdm2
transformed mouse 3T3 
cell double minute 2 17246
ENSMUSG000000201
84
11 14081 NA Acsl1
acyl-CoA synthetase long-
chain family member 1 14081
ENSMUSG000000187
96
12 71911 NA Bdh1
3-hydroxybutyrate 
dehydrogenase, type 1 71911
ENSMUSG000000465
98
13 14857 NA Gsta1
glutathione S-transferase, 
alpha 1 (Ya) 14857
ENSMUSG000000741
83
14 67307 NA Pbld2
phenazine biosynthesis-
like protein domain 
containing 2 67307
ENSMUSG000000200
68
15 64697 NA Keg1 kidney expressed gene 1 64697
ENSMUSG000000246
94
16 12304 NA Pdia4
protein disulfide isomerase 
associated 4 12304
ENSMUSG000000258
23
17 24110 NA Usp18
ubiquitin specific peptidase 
18 24110
ENSMUSG000000301
07
18 21822 NA Tgtp1 T cell specific GTPase 1 21822
ENSMUSG000000789
22
19 20620 NA Plk2 polo-like kinase 2 20620
ENSMUSG000000217
01
20 15360 NA Hmgcs2
3-hydroxy-3-methylglutaryl-
Coenzyme A synthase 2 15360
ENSMUSG000000278
75
21 14073 NA Faah fatty acid amide hydrolase 14073
ENSMUSG000000341
71
22 15496 NA Hsd3b5
hydroxy-delta-5-steroid 
dehydrogenase, 3 beta- 
and steroid delta-
isomerase 5 15496
ENSMUSG000000380
92
23 70789 NA Kynu
kynureninase (L-
kynurenine hydrolase) 70789
ENSMUSG000000268
66
24 231655 NA Oasl1
2'-5' oligoadenylate 
synthetase-like 1 231655
ENSMUSG000000418
27
25 60525 NA Acss2
acyl-CoA synthetase short-
chain family member 2 60525
ENSMUSG000000276
05
26 68636 NA Fahd1
fumarylacetoacetate 
hydrolase domain 
containing 1 68636
ENSMUSG000000453
16
27 74147 NA Ehhadh
enoyl-Coenzyme A, 
hydratase/3-hydroxyacyl 
Coenzyme A 
dehydrogenase 74147
ENSMUSG000000228
53
Database:molecular function       Name:catalytic activity       ID:GO:0003824
C=5105; O=27; E=11.04; R=2.45; rawP=5.83e-07; adjP=4.55e-05
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Index UserID Value Gene Symbol Gene Name EntrezGene Ensembl
1 21822 NA Tgtp1 T cell specific GTPase 1 21822
ENSMUSG000000789
22
2 230073 NA Ddx58
DEAD (Asp-Glu-Ala-Asp) 
box polypeptide 58 230073
ENSMUSG000000402
96
3 56312 NA Nupr1 nuclear protein 1 56312
ENSMUSG000000307
17
4 18489 NA Reg3b
regenerating islet-derived 
3 beta 18489
ENSMUSG000000713
56
5 15958 NA Ifit2
interferon-induced protein 
with tetratricopeptide 
repeats 2 15958
ENSMUSG000000459
32
6 15959 NA Ifit3
interferon-induced protein 
with tetratricopeptide 
repeats 3 15959
ENSMUSG000000748
96
7 58185 NA Rsad2
radical S-adenosyl 
methionine domain 
containing 2 58185
ENSMUSG000000206
41
8 19695 NA Reg3g
regenerating islet-derived 
3 gamma 19695
ENSMUSG000000300
17
9 70789 NA Kynu
kynureninase (L-
kynurenine hydrolase) 70789
ENSMUSG000000268
66
10 66438 NA Hamp2
hepcidin antimicrobial 
peptide 2 66438
ENSMUSG000000569
78
11 17857 NA Mx1
myxovirus (influenza virus) 
resistance 1 17857 NULL
12 100689 NA Spon2
spondin 2, extracellular 
matrix protein 100689
ENSMUSG000000373
79
13 231655 NA Oasl1
2'-5' oligoadenylate 
synthetase-like 1 231655
ENSMUSG000000418
27
Database:biological process       Name:defense response       ID:GO:0006952
C=803; O=13; E=1.72; R=7.55; rawP=8.70e-09; adjP=2.38e-06
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Kidney
Index UserID Value Gene Symbol Gene 
Name
EntrezGene Ensembl
1 
ILMN_258
8249 NA Plin4 perilipin 4 57435
ENSMUS
G0000000
2831
2 
ILMN_121
5446 NA Cidea
cell death-
inducing 
DNA 
fragmenta
tion factor, 
alpha 
subunit-
like 
effector A 12683
ENSMUS
G0000002
4526
3 
ILMN_122
2679 NA Cidec
cell death-
inducing 
DFFA-like 
effector c 14311
ENSMUS
G0000003
0278
4 
ILMN_122
2246 NA Plin2 perilipin 2 11520
ENSMUS
G0000002
8494
Index UserID Value Gene Symbol Gene 
Name
EntrezGene Ensembl
1 
ILMN_259
9794 NA Apoc1
apolipopro
tein C-I 11812
ENSMUS
G0000004
0564
Database:cellular component       Name:lipid particle       ID:GO:0005811
C=43; O=4; E=0.11; R=37.95; rawP=3.58e-06; adjP=8.83e-05
Database:molecular function       Name:carboxylic acid binding       ID:GO:0031406
C=178; O=4; E=0.38; R=10.48; rawP=0.0005; adjP=0.0145
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2 
ILMN_263
4317 NA Slc1a3
solute 
carrier 
family 1 
(glial high 
affinity 
glutamate 
transporte
r), 
member 3 20512
ENSMUS
G0000000
5360
3 
ILMN_125
8600 NA Acaca
acetyl-
Coenzym
e A 
carboxyla
se alpha 107476
ENSMUS
G0000002
0532
4 
ILMN_273
8082 NA Adipoq
adiponecti
n, C1Q 
and 
collagen 
domain 
containing 11450
ENSMUS
G0000002
2878
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